Medicine
Mepron 750 mg/5 mL oral suspension
Mepron 750 mg/5 mL oral suspension is a prescription medicine containing Atovaquone for oral use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Do not freeze. Store at 15°C to 25°C (59°F to 77°F).
Key facts
- Active ingredient (INN)
- Atovaquone
- Brand
- Mepron
- Strength
- 750 mg/5 mL
- Dosage form
- Oral suspension
- Route
- Oral
- Packs
- 42 pouches, 210 mL
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturer
- GlaxoSmithKline
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Do not freeze. Store at 15°C to 25°C (59°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- P01AX06 Atovaquone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 1995
- Identifiers
- RxCUI 211947, 308429DailyMed set ID b426b6bf-f07e-4580-97ae-dfca1ddf5b8fNDC 0173-0547, 0173-0665Application NDA020500
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 42 pouch in 1 dose pack / 5 mL in 1 pouch | 0173-0547-00 | GlaxoSmithKline | 18 September 1998 |
| 210 mL in 1 bottle | 0173-0665-18 | GlaxoSmithKline | 28 February 1995 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 25 November 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Atovaquone 750 mg/5 mL oral suspension.
Clinical summary
Atovaquone is an antimalarial indicated for prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX), among other approved uses. It is available as oral suspension. MedsAcross supplies Atovaquone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AtovaquoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- MEPRON prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Mepron 750 mg/5 mL oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.